The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects.

• Material Type: 博士論文
• Title: The Angiotensin II Receptor Blocker Losartan Sensitizes Human Liver Cancer Cells to Lenvatinib-Mediated Cytostatic and Angiostatic Effects.
• Author/Editor: Takagi, Hirotetsu; Kaji, Kosuke; Nishimura, Norihisa; Ishida, Koji; Ogawa, Hiroyuki; Takaya, Hiroaki; Kawaratani, Hideto; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
• Author Heading: Takagi, Hirotetsu; Kaji, Kosuke; Nishimura, Norihisa; Ishida, Koji; Ogawa, Hiroyuki; Takaya, Hiroaki; Kawaratani, Hideto; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
• Publication, Distribution, etc.: MDPI
• Publication Date: 2021-03-05
• Publication Date (W3CDTF): 2021-03-05
• Alternative Title: アンジオテンシンII 受容体拮抗薬であるロサルタンは、レンバチニブによるヒト肝癌細胞への 細胞増殖抑制性および血管新生抑制効果の感性を向上させる
• Periodical title: Cells
• No. or year of volume/issue: 10 3
• Volume: 10
• Issue: 3
• Pages: Article No.575-
• ISSN (Periodical Title): ISSN : 2073-4409
• Degree grantor/type: 奈良県立医科大学
• Date Granted: 2022-03-15
• Dissertation Number: 甲第813号
• Degree Type: 博士（医学）
• Text Language Code: eng
• Subject Heading: HCC; VEGF; angiotensin-II; angiogenesis; lenvatinib
• Target Audience: 一般
• Note (General): type:Thesis; Molecular targeted therapy with lenvatinib is commonly offered to advanced hepatocellular carcinoma (HCC) patients, although it is often interrupted by adverse effects which require a reduction in the initial dose. Thus, an alternative lenvatinib-based therapy to compensate for dose reduction is anticipated. This study aimed to assess the effect of combination of low-dose of lenvatinib and the angiotensin-II (AT-II) receptor blocker losartan on human HCC cell growth. In vitro studies found that losartan suppressed the proliferation by inducing G1 arrest and caused apoptosis as indicated by the cleavage of caspase-3 in AT-II-stimulated HCC cell lines (Huh-7, HLE, and JHH-6). Losartan attenuated the AT-II-stimulated production of vascular endothelial growth factor-A (VEGF-A) and interleukin-8 and suppressed lenvatinib-mediated autocrine VEGF-A production in HCC cells. Moreover, it directly inhibited VEGF-mediated endothelial cell growth. Notably, the combination of lenvatinib and losartan augmented the cytostatic and angiostatic effects of the former at a low-dose, reaching those achieved with a conventional dose. Correspondingly, a HCC tumor xenograft assay showed that the oral administration of losartan combined with lenvatinib reduced the subcutaneous tumor burden and intratumor vascularization in BALB/c nude mice. These findings support that this regimen could be a viable option for patients intolerant to standard lenvatinib dosage.; 博士（医学）・甲第813号・令和4年3月15日; © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).; identifier:Cells Vol.10 No.3 Article No.575 (2021 Mar); identifier:20734409; identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/3996; identifier:Cells, 10(3): Article No.575
• Access Restrictions: インターネット公開
• Related Material (DOI): 10.3390/cells10030575
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 奈良県立医科大学 : 奈良県立医科大学機関リポジトリ GINMU

Table of Contents

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3996/1/01%e7%94%b2813%e6%9c%ac%e6%96%87%e3%81%ae%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3996/2/02%e7%94%b2813%e5%af%a9%e6%9f%bb%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3996/3/03%e7%94%b2813%e6%9c%ac%e6%96%87.pdf fulltext